Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROSY-S rollover study of anifrolumab continued treatment
2026-526419-13-00Phase 3Authorised
- Sponsor
- AstraZeneca
- Start
- Oct 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 36
01
Overview
Phase 3, open-label, single-arm trial of anifrolumab in systemic sclerosis (SSc), cutaneous lupus erythematosus (CLE), myopathies and 1 more, sponsored by AstraZeneca. Primary endpoint: Safety. Planned start Oct 2026; status: authorised.
02
Drugs
anifrolumab
03
Conditions
systemic sclerosis (SSc)cutaneous lupus erythematosus (CLE)myopathiessystemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2026-526419-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-526419-13-00.